John Vavricka

John Vavricka

Chief Commercial OfficeratAtea Pharmaceuticals· In proxies 2022–2025

Pay in FY2025-12% from the year before · Atea Pharmaceuticals stock +6.6% the same year

John Vavricka was paid $1.2M in FY2025 (Dec), down 12%. Atea Pharmaceuticals stock rose 6.6% that year.

Pay$100 in the stock at the end of FY21 → $40
Pay is from the Summary Compensation Table of each Atea Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Atea PharmaceuticalsPublic company · 4 yr
    • Chief Commercial Officer2022 – Present · 4 yrStock in role -55%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?